tradingkey.logo
tradingkey.logo
Search

European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen

ReutersApr 9, 2025 1:10 PM
facebooktwitterlinkedin

- Halozyme Therapeutics Inc HALO.O:

  • EUROPEAN COMMISSION APPROVED SUBCUTANEOUS DARZALEX® (DARATUMUMAB)-BASED QUADRUPLET REGIMEN FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, REGARDLESS OF TRANSPLANT ELIGIBILITY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI